Lima Memorial Health System Logo
Approximate ER WAIT TIME WAIT TIME MACRO
Lima Memorial eHealth
Careers
Ways to Give

Health Library

Progressive multifocal leukoencephalopathy
     
Print-Friendly
Bookmarks

Progressive multifocal leukoencephalopathy

PML; John Cunningham virus; JCV; Human polyomavirus 2; JC virus

 

Progressive multifocal leukoencephalopathy (PML) is a rare infection that damages the material called myelin that covers and protects nerves in the white matter of the brain.

Causes

 

The John Cunningham virus, or JC virus (JCV), causes PML. JCV is also known as human polyomavirus 2. By age 10, most people have been infected with JCV, but it rarely causes symptoms. The virus remains in the body, but normally is inactive and causes no problems. But people with a weakened immune system are at risk of developing PML. Causes of a weakened immune system include:

  • HIV/AIDS (less common now because of better management of HIV/AIDS).
  • Medicines that suppress the immune system, including monoclonal antibodies. These medicines are used to prevent organ transplant rejection or to treat multiple sclerosis, rheumatoid arthritis and other autoimmune disorders, and related conditions.
  • Cancers, such as leukemia and Hodgkin lymphoma.

 

Symptoms

 

Symptoms may include any of the following:

  • Loss of coordination, clumsiness
  • Loss of language ability (aphasia)
  • Memory loss
  • Vision problems
  • Weakness of the legs and arms that gets worse
  • Personality changes

 

Exams and Tests

 

Your health care provider will perform a physical exam and ask about symptoms.

Tests may include:

  • Brain biopsy (in rare cases)
  • Cerebrospinal fluid analysis and blood test for the JCV
  • CT scan of the brain
  • Electroencephalogram (EEG)
  • MRI of the brain

 

Treatment

 

In people with HIV/AIDS, treatment to strengthen the immune system can lead to recovery from the symptoms of PML. No other treatments have proved effective for PML. Medicines to treat PML are being developed and may be available in the near future.

 

Outlook (Prognosis)

 

PML is a life-threatening condition. Depending on how severe the infection is, more than a third of people diagnosed with PML die within a year. Talk to your provider about care decisions.

 

 

Open References

References

Beckham JD, Solbrig MV, Tyler KL. Viral encephalitis and meningitis. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 78.

Cortese I, Tan CS. JC, BK, and other polyomaviruses: progressive multifocal leukoencephalopathy, BK nephropathy, and Merkel cell carcinoma. In: Blaser MJ, Cohen JI, Holland SM, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 10th ed. Philadelphia, PA: Elsevier; 2026:chap 151.

Hirsch HH. Polyomaviruses. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 341.

BACK TO TOPText only

 
  • Gray and white matter of the brain

    Gray and white matter of the brain

    illustration

  • Leukoencephalopathy

    Leukoencephalopathy

    illustration

    • Gray and white matter of the brain

      Gray and white matter of the brain

      illustration

    • Leukoencephalopathy

      Leukoencephalopathy

      illustration

    A Closer Look

     
       

      Review Date: 1/27/2026

      Reviewed By: Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

      The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language.

      © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

      All content on this site including text, images, graphics, audio, video, data, metadata, and compilations is protected by copyright and other intellectual property laws. You may view the content for personal, noncommercial use. Any other use requires prior written consent from Ebix. You may not copy, reproduce, distribute, transmit, display, publish, reverse-engineer, adapt, modify, store beyond ordinary browser caching, index, mine, scrape, or create derivative works from this content. You may not use automated tools to access or extract content, including to create embeddings, vectors, datasets, or indexes for retrieval systems. Use of any content for training, fine-tuning, calibrating, testing, evaluating, or improving AI systems of any kind is prohibited without express written consent. This includes large language models, machine learning models, neural networks, generative systems, retrieval-augmented systems, and any software that ingests content to produce outputs. Any unauthorized use of the content including AI-related use is a violation of our rights and may result in legal action, damages, and statutory penalties to the fullest extent permitted by law. Ebix reserves the right to enforce its rights through legal, technological, and contractual measures.
      © 1997- adam.comAll rights reserved.